

Montanaro European Companies Trust
Quarterly Commentary – Q4 2020**Market review**

When news of a viral outbreak in China's Hubei Province began to circulate at the beginning of the 2020, few could have imagined the global consequences. In the 21st Century, a virus swept across the world, locked down populations, brought economies to a halt and resulted in over 1.8 million deaths.

As Covid-19 spread across borders and achieved pandemic status, it became clear that little could be done to contain the disease. Initially, fear gripped financial markets. Falls in equity prices were so dramatic that it even led to speculation that some indices might be closed to "calm the herd". Ultimately, investors' fears were soothed by a tidal wave of liquidity unleashed by Central Banks and governments: some \$15 trillion across the G10 countries plus China. As interest rates declined, investors moved into riskier assets and equities staged a swift and strong recovery.

There were some grounds for optimism. Certain Governments were able to relax lockdown restrictions during the Summer and unlocked economies raised hopes of a "V" shaped return to normality. At Halloween, however, Covid cases spiked again and social-distancing restrictions were re-introduced. Yet financial markets did not panic, for November heralded the arrival of three Covid-19 vaccines with high efficacy rates. The "risk-on" accelerator was pressed once again and much maligned "Value" stocks enjoyed a rare moment in the sun as they led markets higher. Even the US Presidential Election – and Donald Trump's unwillingness to admit defeat – did little to perturb the buoyant mood.

What then, did the score card reveal at the end of 2020? European LargeCap suffered as the continent was ravaged by the virus and factories and shops were shuttered, delivering a poor return of -7%. By contrast, SmallCap delivered a positive return of 3% as the asset class benefited from localised improvements in business activity. This marked the ninth year of outperformance versus LargeCap in the past eleven.

Portfolio

During the quarter, the NAV of the Trust increased by 12%, marginally behind the MSCI Europe SmallCap (ex UK) Index as "Value" stock rallied following the vaccine announcements. Over the calendar year, the NAV rose by some 38%, an outperformance of 22%.

The strongest contribution during the quarter came from **Fortnox**, the provider of cloud accounting software, which rose on the back of a positive Q3 report and a bullish broker initiation. **MTU Aero Engines**, the aircraft engine manufacturer, outperformed

as investors anticipated a return to more normal levels of air traffic following the approval of Covid-19 vaccines. **MIPS**, the Swedish maker of helmet inserts preventing head injuries, continued to rally due to growing adoption of their products across bike, ski, safety construction, and motorcycle categories.

The weakest contribution came from **Sartorius Stedim**, the developer of equipment used in the manufacture of biologic drugs, which reported excellent results during the quarter but saw profit taking on the back of the Covid-19 vaccine announcements. **Vitrolife**, the leading supplier of products used for IVF treatments, reported good Q3 results but nevertheless saw some profit taking during the quarter following a strong run. **Tecan**, the Swiss manufacturer of highly-specialised robotic instruments used in life sciences research and diagnostic testing, had a weak quarter, experienced profit taking after a very good run.

Outlook

Many are glad that 2020 is over, a year in which life for billions of people was turned upside down. Yet things may not be much different in 2021, at least for a few months. Further lockdown restrictions have been announced due to a more virulent strain of the Covid-19 virus. For now, the virus is calling the shots, continuing to threaten our health, economies and freedom.

However, the rollout of vaccines should allow a return to greater normality, hopefully by the Summer. What world will we face then? There will be a monumentally large debt burden as Government support during the crisis has been unprecedented. Therefore, this era of extraordinary monetary policy is likely to continue. Sustained low interest rates would allow the economy to recover, perhaps quite strongly, once the battle against the virus is perceived to be won.

From an equity perspective, this may mean that heavily stressed companies that have suffered the most lead an initial rally in markets. This would benefit “Value” companies as we saw last November. We would, however, urge a note of caution to those who believe that 2021 will be the year that low quality companies outperform. Once Covid-19 is behind us, consumers may shift uneasily between exuberance that their freedoms have been restored and nervousness about the future, particularly for those working in industries that have been structurally changed by the last few months. It may not be time to throw caution to the wind.

We will continue to invest in the highest quality companies that we can find, for, in our view, these will be the long-term winners. Many of our companies can look forward to exciting futures: healthcare businesses responding to the need for better preventative solutions and greater demand for new forms of treatment; technology

companies creating a more connected, digital and safer on-line world; companies with strong management teams who have looked after their employees during this crisis and have emerged stronger; and those doing their bit to tackle important global issues such as climate change.

We wish you and your families good luck and every success in the months ahead. Stay safe, happy, and hopeful for a prosperous future and a return to normal.

The views expressed in this article are those of the author at the date of publication and not necessarily those of Montanaro Asset Management Ltd. The information contained in this document is intended for the use of professional and institutional investors only. It is for background purposes only, is not to be relied upon by any recipient, and is subject to material updating, revision and amendment and no representation or warranty, express or implied, is made, and no liability whatsoever is accepted in relation thereto. This memorandum does not constitute investment advice, offer, invitation, solicitation, or recommendation to issue, acquire, sell or arrange any transaction in any securities. References to the outlook for markets are intended simply to help investors with their thinking about markets and the multiple possible outcomes. Investors should always consult their advisers before investing. The information and opinions contained in this article are subject to change without notice.